NCT04799847 2023-02-13Catumaxomab in Patients With Non-Muscle-Invasive Bladder Cancer Who Have Failed or Are Intolerant to BCG VaccineLintonPharm Co.,Ltd.Phase 1/2 Unknown161 enrolled